A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients

The goal of this investigator-initiated, a single-arm, open-label, pilot study is to investigate the safety, tolerability, and efficacy of Intravenous CD-801 treatment in subjects with advanced hepatocellular carcinoma(HCC). Condition of disease: advanced hepatocellular carcinoma. Intervention： CD-801 will be administered intravenously for the treatment of HCC. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response. The trial is structure

Trial Details

NCT ID
NCT06418659
Phase
EARLY_PHASE1
Sponsor
Shanghai Changzheng Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • CD-801
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Males or females, aged 18 years or older.
  • Subjects must have confirmed diagnosis of HCC with any of the following criteria according to the American Association for the Study of Liver Disea…
  • Unresectable HCC.
  • Subjects were not eligible for locoregional or systemic therapies, or had disease progression, or would not benefit after at least one of the conve…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →